GRIM
LFCR icon

Greenhaven Road Investment Management’s Lifecore Biomedical LFCR Stock Holding History

Greenhaven Road Investment Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.8M Sell
3,190,769
-346,804
-10% -$1.75M 10.88% 4
2026
Q1 		$13.2M Sell
3,537,573
-145,000
-4% -$1M 9.05% 5
2025
Q4 		$30.1M Sell
3,682,573
-12,259
-0.3% -$90.7K 5.07% 4
2025
Q3 		$27.2M Hold
3,694,832
– – 4.01% 7
2025
Q2 		$30M Buy
3,694,832
+78,686
+2% +$530K 10.28% 3
2025
Q1 		$25.5M Hold
3,616,146
– – 10.38% 4
2024
Q4 		$26.9M Buy
3,616,146
+1,387,362
+62% +$8.86M 4.3% 5
2024
Q3 		$11M Buy
2,228,784
+12,660
+0.6% +$66.1K 4.67% 9
2024
Q2 		$11.4M Buy
2,216,124
+72,106
+3% +$427K 5.27% 7
2024
Q1 		$11.4M Sell
2,144,018
-222,938
-9% -$1.59M 4.82% 6
2023
Q4 		$14.7M Buy
2,366,956
+173,623
+8% +$1.21M 6.16% 6
2023
Q3 		$16.5M Buy
2,193,333
+290,694
+15% +$2.66M 8.3% 6
2023
Q2 		$18.4M Buy
1,902,639
+868,190
+84% +$5.3M 9.32% 5
2023
Q1 		$3.9M Buy
+1,034,449
New +$5.77M 2.24% 9

Other funds holding LFCR

WC
Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return
3C
325 Capital New York $419M AUM 75.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return

Greenhaven Road Investment Management's LFCR Position: Q2 2026 in Review

Greenhaven Road Investment Management reduced its Lifecore Biomedical (LFCR) stake by 9.8% in Q2 2026, selling an estimated $1.75M and leaving 3,190,769 shares worth $16.8M. The position accounts for 10.88% of the portfolio, ranked #4.

Greenhaven Road Investment Management first reported a position in LFCR in Q1 2023 and has held it in 14 quarters since. The position peaked at $30.1M in Q4 2025. 99 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

  • Greenhaven Road Investment Management held 3,190,769 shares of Lifecore Biomedical worth $16.8M as of Q2 2026.
  • Greenhaven Road Investment Management sold 346,804 Lifecore Biomedical shares in Q2 2026, an estimated $1.75M.
  • Lifecore Biomedical made up 10.88% of Greenhaven Road Investment Management's portfolio in Q2 2026, its #4 holding.
  • Greenhaven Road Investment Management first reported a position in Lifecore Biomedical in Q1 2023 and has held it in 14 quarters since.
  • Greenhaven Road Investment Management's Lifecore Biomedical position peaked at $30.1M in Q4 2025.
  • 99 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on Greenhaven Road Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.